Drug Approval | February 03, 2022
USFDA approves first generic of Restasis
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
The study will be published on the pre-print server, medRXiv, shortly
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Subscribe To Our Newsletter & Stay Updated
